RT Journal Article SR Electronic T1 Long-term Outcome in Patients with Recurrent Malignant Glioma Treated with Perillyl Alcohol Inhalation JF Anticancer Research JO Anticancer Res FD International Institute of Anticancer Research SP 5625 OP 5631 VO 33 IS 12 A1 CLOVIS O. DA FONSECA A1 RAPHAEL M. TEIXEIRA A1 JÚLIO CESAR T. SILVA A1 JULIANA DE SALDANHA DA GAMA FISCHER A1 OSÓRIO C. MEIRELLES A1 JOSE ALBERTO LANDEIRO A1 THEREZA QUIRICO-SANTOS YR 2013 UL http://ar.iiarjournals.org/content/33/12/5625.abstract AB Aim: This retrospective study aimed to evaluate the long-term response and toxicity of recurrent malignant glioma patients to inhalation chemotherapy with perillyl alcohol (POH). Patients and Methods: The cohort included 117 men and 81 women with primary glioblastoma multiforme (GBM; n=154), grade III astrocytoma (AA; n=26) and anaplastic oligodendroglioma (AO; n=5). POH inhalation schedule 4-times daily started with 66.7 mg/dose; 266 mg/day and escalated up to 133.4 mg/dose; 533.6 mg/day. Clinical toxicity and overall survival following treatment were compared with tumor size, topography, extent of peritumoral edema and histological classification. Results: Adhesion to the protocol was high (>95%), POH (533.6 mg/daily) occasionally caused nose soreness but rarely nosebleed. Tumor size, peritumoral edema and the oligodendroglial component influenced response to treatment. Conclusion: After 4 years under exclusive POH treatment, 19% of patients still remain in clinical remission. Long-term POH inhalation chemotherapy is a safe and non-invasive strategy efficient for recurrent malignant glioma.